Affimed cuts up to 50% of employees to support clinical projects, CEO departsnews2024-01-08T14:36:56+00:00January 8th, 2024|Endpoints News|
#JPM24: J&J makes $2B push into ADCs with Ambrx buyout in oncology deal spreenews2024-01-08T13:14:16+00:00January 8th, 2024|Endpoints News|
#JPM24: Merck to acquire Harpoon Therapeutics for $680Mnews2024-01-08T13:07:53+00:00January 8th, 2024|Endpoints News|
#JPM24: Novartis licenses two cardiovascular RNAi drugs from Shanghai Argo for $185M upfrontnews2024-01-08T11:42:47+00:00January 8th, 2024|Endpoints News|
New David Liu study details virus-like delivery system for prime editingnews2024-01-08T10:00:22+00:00January 8th, 2024|Endpoints News|
#JPM24: Novartis to acquire Calypso Biotech for $250M upfrontnews2024-01-08T09:49:44+00:00January 8th, 2024|Endpoints News|
Vertex pauses diabetes islet cell therapy study after two patient deaths it says are unrelated to drugnews2024-01-07T22:12:46+00:00January 7th, 2024|Endpoints News|
Alphabet’s AI unit Isomorphic inks drug discovery deals with Eli Lilly, Novartis for up to $3Bnews2024-01-07T17:00:58+00:00January 7th, 2024|Endpoints News|
Cerevel failed to draw Pfizer into a bidding war, but got AbbVie to up its price anyway, filing showsnews2024-01-06T14:16:24+00:00January 6th, 2024|Endpoints News|
Roche leads pre-JPM deal spree; Roger Perlmutter’s new pharma force; Inside Sage’s big triumph and failure; Late Friday IPO filings; All new drugs in 2023; and morenews2024-01-06T11:00:42+00:00January 6th, 2024|Endpoints News|
